1-(2-氯-6-甲基吡啶-3-基)乙酮 | 49667-29-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(2-氯-6-甲基吡啶-3-基)乙酮
• 英文名称: 1-(2-chloro-6-methyl-pyridin-3-yl)-ethanone
• 英文别名: 2-Acetyl-2-chlor-6-methylpyridin；3-Acetyl-2-chlor-6-methylpyridin；1-(2-Chloro-6-methylpyridin-3-YL)ethanone
• CAS: 49667-29-0
• 化学式: C₈H₈ClNO
• 分子量: 169.611
• InChiKey: SHMWLYUKXRLPJV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  1-(2-氯-6-甲基吡啶-3-基)乙酮 在 10% Pd/C 、 氢气 、 palladium diacetate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 sodium hydroxide 作用下， 以 甲醇 为溶剂， 生成
  参考文献：
  名称：

  Discovery of a novel series of 4-quinolone JNK inhibitors

  摘要：

  A novel series of highly selective JNK inhibitors based on the 4-quinolone scaffold was designed and synthesized. Structure based drug design was utilized to guide the compound design as well as improvements in the physicochemical properties of the series. Compound (13c) has an IC50 of 62/170 nM for JNK1/2, excellent kinase selectivity and impressive efficacy in a rodent asthma model. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2012.10.066
• 作为产物：
  描述：

  2-氯-6-甲基烟酸 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 为溶剂， 生成 1-(2-氯-6-甲基吡啶-3-基)乙酮
  参考文献：
  名称：

  Discovery of a novel series of 4-quinolone JNK inhibitors

  摘要：

  A novel series of highly selective JNK inhibitors based on the 4-quinolone scaffold was designed and synthesized. Structure based drug design was utilized to guide the compound design as well as improvements in the physicochemical properties of the series. Compound (13c) has an IC50 of 62/170 nM for JNK1/2, excellent kinase selectivity and impressive efficacy in a rodent asthma model. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2012.10.066

文献信息

• EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO
  申请人：eFFECTOR Therapeutics, Inc.

  公开号：US20170145026A1

  公开（公告）日：2017-05-25

  The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R 1 , R 2 , R 3a , R 3b , R 4a , R 4b and R 5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

  本发明提供了根据式I合成的化合物、药用可接受的配方和用途，或其立体异构体、互变异构体或药用可接受的盐。对于式I化合物X、Y、R1、R2、R3a、R3b、R4a、R4b和R5如规范中所定义。这些创新的式I化合物是eIF4A的抑制剂，在许多治疗应用中发挥作用，包括但不限于治疗炎症和各种癌症。
• Dihydroquinone and dihydronaphthridine inhibitors of JNK
  申请人：Abbot Sarah C.

  公开号：US20080287458A1

  公开（公告）日：2008-11-20

  Compounds of formula I are effective modulators of JNK: wherein X is CR 11 or N; Y is —C(O)R 3 , 5-membered heteroaryl, or 5-membered heterocyclyl; Z is phenyl, cycloalkyl, heterocyclyl or heteroaryl, and is substituted with R 1 and R 2 ; R 1 and R 2 are each independently H, halo, CN, lower alkyl, or —Y 1 —Y 2 —Y 3 —R 8 , or R 1 and R 2 together form —O(CH 2 ) n O—, where n is 1 or 2; Y 1 is —O—, —C(O)—, —C(O)O—, —C(O)NR 9 —, —NR 9 C(O)—, —S—, —SO 2 —, or a bond; Y 2 is cycloalkylene, heterocycloalkylene, lower alkylene or a bond; Y 3 is —O—, —C(O)—, —C(O)O—, —C(O)NR 9 —, —NR 9 C(O)—, —SO 2 —, or a bond; R 8 is H, lower alkyl, lower alkoxy, cycloalkyl, heterocycloalkyl, or —NR 9 R 10 , wherein R 8 other than H is optionally substituted with lower alkyl, halo, —CF 3 , or —OH; R 9 and R 10 are each independently H or lower alkyl; R 3 is OH, lower alkyl, lower alkoxy, (lower alkoxy)-lower alkoxy, or —NR 9 R 10 ; R 4 is lower alkyl, phenyl, heterocyclyl, cycloalkyl, heterocycloalkyl, or heteroaryl, and is optionally substituted with lower alkyl, hydroxy, lower alkoxy, halo, nitro, amino, cyano, or halo-lower alkyl; R 5 and R 6 are each independently H, halo, cyano, lower alkyl, —CF 3 , lower alkoxy, —OCHF 2 , —NO 2 , or —NR 9 R 10 ; R 7 is H, F, Cl, methyl, or OH; R 11 is H, lower alkyl, lower cycloalkyl, or phenyl; or a pharmaceutically acceptable salt thereof.

  式I的化合物是JNK的有效调节剂： 其中 X为CR11或N； Y为—C(O)R3，5-成员杂芳基，或5-成员杂环烷基； Z为苯基，环烷基，杂环烷基或杂芳基，并且被R1和R2取代； R1和R2各自独立地为H，卤素，CN，较低烷基，或—Y1—Y2—Y3—R8，或R1和R2一起形成—O(CH2)nO—，其中n为1或2； Y1为—O—，—C(O)—，—C(O)O—，—C(O)NR9—，—NR9C(O)—，—S—，—SO2—，或键； Y2为环烷亚烷基，杂环烷亚烷基，较低烷基亚烷基或键； Y3为—O—，—C(O)—，—C(O)O—，—C(O)NR9—，—NR9C(O)—，—SO2—，或键； R8为H，较低烷基，较低烷氧基，环烷基，杂环烷基，或—NR9R10，其中R8除H外可选择地被较低烷基，卤素，—CF3，或—OH取代； R9和R10各自独立地为H或较低烷基； R3为OH，较低烷基，较低烷氧基，(较低烷氧基)-较低烷氧基，或—NR9R10； R4为较低烷基，苯基，杂环烷基，环烷基，杂环烷基，或杂芳基，并且可选择地被较低烷基，羟基，较低烷氧基，卤素，硝基，氨基，氰基，或卤素较低烷基取代； R5和R6各自独立地为H，卤素，氰基，较低烷基，—CF3，较低烷氧基，—OCHF2，—NO2，或—NR9R10； R7为H，F，Cl，甲基，或OH； R11为H，较低烷基，较低环烷基，或苯基； 或其药用可接受盐。
• FUSED HETEROARYL MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kappaB ACTIVITY AND USE THEREOF
  申请人：Duan Jingwu

  公开号：US20110002952A1

  公开（公告）日：2011-01-06

  Novel non-steroidal compounds are provided which are useful in treating diseases or disorders associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity, including metabolic and inflammatory and immune diseases or disorders, having the structure of formula (I): an enantiomer, diastereomer, or tautomer thereof, or a prodrug ester thereof, or a pharmaceutically-acceptable salt thereof, in which: Z is heterocyclo or heteroaryl; -A is a 5- to 8-membered carbocyclic ring or a 5- to 8-membered heterocyclic ring; B1 and B2 rings are pyridyl rings, wherein the B1 and B 2 rings are each fused to the A ring and the B1 ring is optionally substituted by one to three groups which are the same or different and are independently selected from R 1 , R 2 , and R 4 , and the B2 ring is optionally substituted by one to three groups which are the same or different and are independently selected from R3, R 7 , and R 3 71, J 2 , and J3 are at each occurrence the same or different and are independently -AIQA2-; Q is a bond, O, S, S(0), or S(O)2; A1 and A2 are the same or different and are at each occurrence independently selected from a bond, C1-3 alkylene, substituted C 1-3 alkylene, C24 alkenylene, and substituted C24 alkenylene, provided that A 1 and A2 are chosen so that ring A is a 5- to 8-membered carbocyclic or heterocyclic ring; R 1 to R 11 are as defined herein.

  提供了一种新型的非类固醇化合物，其在治疗与糖皮质激素受体、AP-1和/或NF-κB活性调节相关的疾病或疾病中具有用途，包括代谢性、炎症和免疫性疾病或疾病，其具有以下结构（I）的对映体、顺反异构体或互变异构体，或其前药酯，或其药学上可接受的盐，其中：Z是杂环或杂环芳基；-A是5-至8-成员的碳环或5-至8-成员的杂环；B1和B2环是吡啶环，其中B1和B2环各与A环融合，B1环可选地被1至3个基取代，所述基是相同或不同的，且独立地从R1、R2和R4中选择，B2环可选地被1至3个基取代，所述基是相同或不同的，且独立地从R3、R7和R371、J2和J3中选择，每次出现时，J2和J3是相同或不同的，且独立地为-AIQA2-；Q是键，O、S、S（0）或S（O）2；A1和A2是相同或不同的，且每次出现时独立地从键、C1-3烷基、取代C1-3烷基、C24烯基和取代C24烯基中选择，前提是A1和A2被选择为环A是5-至8-成员的碳环或杂环；R1至R11如本文所定义。
• DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2148862A1

  公开（公告）日：2010-02-03
• US8163906B2
  申请人：——

  公开号：US8163906B2

  公开（公告）日：2012-04-24